Quest Diagnostics Inc vs Equinix Inc — how do they compare? Quest Diagnostics Inc trades at $238.01 (market cap $26.21B), while Equinix Inc trades at $1,066.01 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 3.9× Quest Diagnostics Inc's market cap, and Equinix Inc pays the higher dividend (2%). Which is the better fit depends on your goals.
| DGX | EQIX | |
|---|---|---|
Market Cap | $26.21B | $101.87B |
Sector | Health | Real Estate |
52-Week High | $238.50 | $1.12K |
52-Week Low | $173.49 | $726.09 |
Enterprise Value | $31.97B | $123.00B |
Dividend Yield | 1.45% | 2% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Equinix (EQIX) trades at $1,049.99, up 0.63% today, with a neutral technical signal as it hovers near resistance at $1,050. The stock shows strong analyst support (74.51% buy ratings) and a consensus price target of $1,120, driven by robust revenue growth, expanding net income margins to 15.63% in 2025, and positive news on AI infrastructure demand. However, high valuation ratios like a P/E of 66.44 and significant capital expenditures pose challenges.
The outlook remains positive due to sustained digital infrastructure demand and raised long-term guidance, but risks include elevated debt levels and earnings misses in recent quarters. Investors should weigh growth prospects against premium valuations and cash flow pressures from heavy investments.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →